Tag Archives: Los Angeles

ingredientscounter

Pizza Studio Opens First Phoenix Location

Los Angeles-based fast-casual restaurant, Pizza Studio, will expand into Phoenix after signing a multi-unit development agreement for 20 new locations in the Phoenix area over the next five years. The first location will open in CityScape on March 10, 2014 at 11 W. Washington Street, Suite 120.

“CityScape will be our flagship restaurant in downtown Phoenix,” said John Lutz, COO. “Whether it’s a quick business lunch, dropping in before a ball game, on the way to a concert or just enjoying a day in our beautiful downtown area, Pizza Studio will serve as a great dining option.”

Lutz is a veteran in the restaurant industry with 30 years of experience. He received a Bachelor of Science degree in business from the University of Hawaii. Most recently with Red Robin Gourmet Burgers, Lutz has provided leadership and guidance on both the corporate and franchise side of the restaurant industry. After becoming interested in the fast-casual pizza segment, Pizza Studio was a natural fit for Lutz. He says, “The Pizza Studio team has done an incredible job creating the vision, fundamentals, culture and community spirit of the brand.” Lutz signed the multi-unit agreement with Pizza Studio as chief operating officer in January.

Pizza Studio is a fast-casual franchise concept that invites guests to create their own custom pizza masterpiece. A wide assortment of crusts, specialty sauces, premium meats, fresh and roasted vegetables and the highest quality ingredients are offered at affordable prices. The company is known for its variety of flavors of their proprietary thin, light and crispy crusts with unlimited toppings of sauces, cheeses, nitrate-free meats and fresh-cut and roasted vegetables for each custom-built pizza creation.

Lutz is delighted to bring Pizza Studio to CityScape. There are currently a few sites under review for upcoming locations. All 20 locations will open within five years.
Since its founding in 2012, Pizza Studio has signed development agreements with several experienced multi-unit operators for 175 units.

prevention trial - brain scan images

Ivy Foundation Grants Over $9M for Brain Cancer Research

The Ben & Catherine Ivy Foundation (Ivy Foundation) announced its 2012 grant recipients, which total more than $9 million in funding for brain cancer research. The Ivy Foundation is the largest privately funded brain cancer research foundation in North America. Catherine Ivy is the founder and president of the Ivy Foundation, which has a research funding focus on glioblastoma multiforme (GBM), the most common and deadliest of malignant primary brain tumors in adults.

The Ivy Foundation awarded the following grants and/or provided funding in 2012:

· $2,500,000 over three years:  Principal Investigator, Greg D. Foltz, M.D., Director, The Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Medical Center
· $5,000,000 over five years:  Principal Investigators, John Carpten, Ph.D. and David Craig, Ph.D., Translational Genomics Research Institute (TGen) – a collaborative effort with University of California, San Francisco; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; Dana Farber/Harvard Cancer Center; MD Anderson; and University of Utah
· $45,000 annually: Principal Investigator, Brandy Wells, Translational Genomics Research Institute (TGen), for the Ivy Neurological Sciences Internship program
· Over $2 million paid out in 2012 for previously committed multi-year brain cancer research grants

“We are encouraged and remain strongly committed to moving the progress forward for patients diagnosed with brain cancer,” said Ivy. “The 2012 Ivy Foundation grant recipients are important strategic partners in our objective to double the life expectancy of people diagnosed with GBM within the next seven years.”

law.courts

Polsinelli Shughart Shortens Firm Name

Polsinelli Shughart PC will shorten the firm name to Polsinelli PC effective late April, 2013.

The firm’s February 2009 combination with Shughart Thomson & Kilroy was preceded by several smaller mergers and acquisitions. The firm has added over 150 attorneys in the four years since the Shughart Thomson merger. Today, the national law firm has more than 630 attorneys in 16 cities including Chicago, Dallas, Denver, Kansas City, Los Angeles, New York, Phoenix, St. Louis, and Washington, D.C.

“While our legacy firms and our history provides our foundation, we have become more than the sum of our parts. Most importantly we are all one firm today and our clients already refer to us as Polsinelli,” said Chairman Russ Welsh. “The owners agreed using one name reflects we are one firm from coast to coast.”

In its 40-year history Polsinelli has had multiple firm names including Polsinelli Shalton Flanigan Suelthaus just before the firm successfully merged with Shughart Thomson & Kilroy and adopted the combined name of Polsinelli Shughart. The merger added Shughart’s well recognized extensive litigation experience to the firm’s established and growing corporate, healthcare, real estate and financial services practices. Adopting one name reflects true integration of services and firm culture.

“This decision reflects branding trends in legal and other professional services which have emulated longstanding practices in consumer marketing,” said Chief Marketing Officer, Allison Yurman. “From a strategic point of view, building brand equity around one name is more viable, and this change leverages existing name awareness by focusing on the shorthand already in use by clients.”

Welsh said the Shughart merger in 2009 brought critical strength in litigation and Shughart’s long, impressive history in Kansas City since the 1940’s. Many of the original Shughart attorneys hold key leadership positions at Polsinelli as practice group chairs and board members.

“We would not be where we are today without those who joined the firm through mergers and laterally.” said Welsh. “When we first merged with Shughart we all joked that both names were a mouthful. But the core reason for the name change is that it reflects who we are now and where we are headed strategically. We are confident the one name, Polsinelli, is easier for clients and will help us strengthen our national identity.”

molecular

Phoenix Children’s Hospital, TGen create Molecular Medicine Institute

Phoenix Children’s Hospital announced the creation of the Ronald A. Matricaria Institute of Molecular Medicine Tuesday, in a joint venture with The Translational Genomics Research Institute (TGen) and The University of Arizona’s College of Medicine.

The three organizations are joining forces with the hopes of unlocking genetic codes in child, adolescent and young adult cancer patients and develop drug therapies in real time to improve the outcome and treatment in these young demographics.

“Our goal is to bring genomics to the forefront of pediatrics,” said Robert L. Meyer, Phoenix Children’s president and CEO. “Research and development of novel treatments for pediatric diseases has fallen short over past decades.”

The reason why the Ronald A. Matricaria Institute of Molecular Medicine is focusing on young patients is because there have been hardly any new therapies introduced to this population in the past two decades. The new institute hopes that clinical studies on children will lead to a better understanding of specific differences between children and adults, which will hopefully lead to the development of safer, more effective and more age-appropriate drug treatments that can be provided in a faster amount of time.

“A challenge with existing molecular medicine programs is the amount of time it takes to develop a new drug or treatment,” Meyer said. “Our collaboration with TGen and University of Arizona opens the doors to making a portfolio of drugs and compounds available immediately.”

The institute will also focus their clinical studies based on underlying genetic and molecular functions of different pediatric cancers, rather than specifically on tumor type. Furthermore, physicians will then create various treatment plans specifically for each patient treated based on the drug therapy that will attack and correct the malfunctioning genes.

With the start of the new institute, a special team of physician scientists will be brought on board to help start out the genomic profiling: Dr. Timothy Triche, a pediatric pathologist and former director of the Center for Personalized Medicine at Children’s Hospital in Los Angeles; Dr. Robert Arceci, a pediatric oncologist from Johns Hopkins University; and Dr. Daniel D. Von Hoff, a medical oncologist at TGen.

“We are trying to figure out a way to have children get appropriate drugs,” said Dr. Robert Arceci. “We all want to know what causes diseases and how we can treat them and I think it takes a special team of people to do this and it takes a lot of unselfish commitment.”

A founding member from whom the institute gets its name, Ronald A. Matricaria, a member of the board of directors for the Phoenix Children’s Hospital, is excited and hopeful for what the new institute is capable of doing in the world of pediatric care.

“Based on my knowledge of the institute and many years of working in the medical field, I’m confident that we can chart a new course for addressing the unique needs of children with cancer and other life-threatening diseases,” Matricaria said. “We could have a huge impact on children’s live and what could be better than that.